Hepatitis CDonald Jensen, Seng-Lai Tan, Nancy Reau, Yupeng He The hepatitis C virus (HCV) is a significant public health problem of international importance. HCV is capable of establishing chronic infections resulting in progressive liver damage and other problems. Current drug therapies are ineffective, highlighting the need for better antiviral drugs. Recent research in HCV genetics and molecular biology have led to significant advances in our understanding of the life cycle of this important pathogen and may ultimately lead to better antiviral strategies. The editors of this book have recruited experts from around the world to produce a timely and well-compiled review of current HCV research, with an emphasis on antiviral drug development. The chapters provide in-depth reviews of the most critical areas of research. Topics include: the HCV life cycle * HCV assays * HCV resources * HCV databases * HCV infection systems * models of hepatitis C infections * overview of the drug pipeline * clinical trial design * clinical virology and drug development * NS3 protease inhibitors * NS3-NS4A complex inhibitors * NS3 helicase inhibitors * NS4B targets and inhibitors * NS5A inhibitors * nucleoside inhibitors * NS5B polymerase inhibitors * glycoprotein-dependent entry * host cell targets and inhibitors * innate immunity for HCV antiviral therapy. |
Contents
2 Epidemiology of Hepatitis C | 2 |
3 Natural History of Hepatitis C | 10 |
4 Diagnostic Testing | 17 |
5 Pathology of Viral Hepatitis C | 17 |
6 Acute Hepatitis C | 17 |
7 Chronic Hepatitis C | 17 |
8 Extrahepatic Manifestations of Hepatitis C | 17 |
9 Hepatitis C in Liver Transplantation | 17 |
10 Treatment of Hepatitis C | 17 |
Other editions - View all
Hepatitis C: Antiviral Drug Discovery and Development Seng-Lai Tan,Yupeng He No preview available - 2011 |
Common terms and phrases
12 weeks 24 weeks 48 weeks achieve SVR acute hepatitis adverse events African American alfa-2a and ribavirin anemia anti-HCV therapy antibody associated chronic hepatitis cirrhosis clinical co-administered co-infection combination therapy cyclophilin DAAs decompensation discontinuation dose reduction drug efficacy England Journal evaluate fibrosis follow-up Gastroenterology genotype 1 infection genotype 1 patients hemodialysis hepatitis C infection hepatitis C virus hepatocytes Hepatology histologic increased interferon alfa-2b IU/mL Journal of Hepatology Journal of Medicine Lawitz liver biopsy liver disease liver transplantation McHutchison mg/day monotherapy NEJM neutropenia NS5A patients with chronic patients with genotype patients with HCV PEG-IFN PEG/RBV peginterferon alfa-2a peginterferon and ribavirin pegylated pegylated interferon phase placebo polymerase inhibitor population protease inhibitor proteins recurrence regimen relapse renal replication ribavirin risk factors side effects Study Design SVR rates symptoms telaprevir testing treated treatment of hepatitis treatment-naïve patients trial undetectable versus VICTRELIS viral load virus infection voriconazole



